Clarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Selling, General & Admin

Selling, General & Admin expenses for CRXT.

Quarterly SG&A Expenses

$12.31M

↓ 17.12% YoY

As of Jun 30, 2022

Annual SG&A Expenses (TTM)

$60.81M

↑ 105.38% YoY

Trailing 12 months ending Jun 30, 2022

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin